therapeuticЮжно-Российский журнал терапевтической практикиSouth Russian Journal of Therapeutic Practice2712-81563033-8344РостГМУ10.21886/2712-8156-2020-1-2-93-101therapeutic-38Research ArticleОБЗОРЫREVIEWSДиабетическая кардиомиопатия: определение, критерии диагноза, направления терапии и предупреждение сердечной недостаточностиDiabetic cardiomyopathy: definition, diagnosis criteria, treatment directions and prevention of heart failurehttps://orcid.org/0000-0001-7003-5186КозиоловаН. А.KoziolovaN. A.

Козиолова Наталья Андреевна, доктор медицинских наук, профессор, заведующая кафедрой пропедевтики внутренних болезней №2

Пермь

Natalya A. Koziolova, Dr. Ci. (Med.), Prof.

Perm

nakoziolova@mail.ruhttps://orcid.org/0000-0003-1103-3812КараваевП. Г.KaravaevP. G.

Караваев Павел Георгиевич, ассистент кафедры пропедевтики внутренних болезней №2

Пермь

Pavel G. Karavaev

Perm

pakarawaew@mail.ruhttps://orcid.org/0000-0002-8769-7335ВекличА. С.VeklichA. S.

Веклич Андрей Станиславович, ассистент кафедры пропедевтики внутренних болезней №2

Пермь

Andrey S. Veklich

Perm

andrei_veklich@mail.ruФГБОУ ВО «Пермский государственный медицинский университет имени академика Е.А. Вагнера» Минздрава РоссииРоссияAcademician Ye.A. Wagner Perm State Medical UniversityRussian Federation2020260820201293101Copyright © Козиолова Н.А., Караваев П.Г., Веклич А.С., 20202020Козиолова Н.А., Караваев П.Г., Веклич А.С.Koziolova N.A., Karavaev P.G., Veklich A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.therapeutic-j.ru/jour/article/view/38

В тематическом обзоре обсуждены различные точки зрения, касающиеся терминологии, диагностических критериев, трудностей оценки распространенности и стадий течения диабетической кардиомиопатии, представлены используемые в клинической практике и потенциальные инструментальные, лабораторные методы диагностики, приведены лечебные методики и стратегические направления терапии данного состояния и профилактики хронической сердечной недостаточности.

The topical review discusses various points of view related to terminology, diagnostic criteria, difficulties in assessing the prevalence and stages of diabetic cardiomyopathy, presents used in clinical practice and potential instrumental and laboratory diagnostic methods, provides therapeutic methods and strategic directions for the treatment of this condition and the prevention of chronic heart failure.

обзордиабетическая кардиомиопатиядиагностические критериилечениепрофилактика сердечной недостаточностиreviewdiabetic cardiomyopathydiagnostic criteriatreatmentprevention of heart failureReferencesTrachanas K., Sideris S., Aggeli C., Poulidakis E., Gatzoulis K., Tousoulis D., et al. Diabetic cardiomyopathy: from pathophysiology to treatment. Hellenic J Cardiol.2014;55:411– 421. PMID: 25243440Trachanas K., Sideris S., Aggeli C., Poulidakis E., Gatzoulis K., Tousoulis D., et al. Diabetic cardiomyopathy: from pathophysiology to treatment. Hellenic J Cardiol.2014;55:411– 421. PMID: 25243440Lundbaek K. Diabetic angiopathy. A specific vascular disease. Lancet. 1954;263:377–379. https://doi.org/10.1016/S0140-6736(54)90924-1Lundbaek K. Diabetic angiopathy. A specific vascular disease. Lancet. 1954;263:377–379. https://doi.org/10.1016/S0140-6736(54)90924-1Rubler S., Dlugash J., Yuceoglu Y.Z., Kumral T., Branwood A.W., Grishman A., et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30:595- 602. https://doi.org/10.1016/0002-9149(72)90595-4Rubler S., Dlugash J., Yuceoglu Y.Z., Kumral T., Branwood A.W., Grishman A., et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30:595- 602. https://doi.org/10.1016/0002-9149(72)90595-4Kannel W.B., Hjortland M., Castelli W.P. Role of diabetes in congestive heart failure; the Framingham study. Am J Cardiol. 1974;34:29–34. https://doi.org/10.1016/0002-9149(74)90089-7Kannel W.B., Hjortland M., Castelli W.P. Role of diabetes in congestive heart failure; the Framingham study. Am J Cardiol. 1974;34:29–34. https://doi.org/10.1016/0002-9149(74)90089-7Penpargkul S., Fein F., Sonnenblick E.H., Scheuer J. Depressed cardiac sarcoplasmic reticular function from diabetic rats. J Mol Cell Cardiol. 1981;13:303-9. https://doi.org/10.1016/0022-2828(81)90318-7Penpargkul S., Fein F., Sonnenblick E.H., Scheuer J. Depressed cardiac sarcoplasmic reticular function from diabetic rats. J Mol Cell Cardiol. 1981;13:303-9. https://doi.org/10.1016/0022-2828(81)90318-7Trost S.U., Belke D.D., Bluhm W.F., Meyer M., Swanson E., Dillmann W.H. Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes. 2002;51:1166–71. https://doi.org/10.2337/diabetes.51.4.1166Trost S.U., Belke D.D., Bluhm W.F., Meyer M., Swanson E., Dillmann W.H. Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes. 2002;51:1166–71. https://doi.org/10.2337/diabetes.51.4.1166Lorenzo-Almorós A., Tuñón J., Orejas M., Cortés M., Egido J., Lorenzo Ó. Diagnostic approaches for diabetic cardiomyopathy. Cardiovasc Diabetol. 2017;16(1):28. https://doi.org/10.1186/s12933-017-0506-xLorenzo-Almorós A., Tuñón J., Orejas M., Cortés M., Egido J., Lorenzo Ó. Diagnostic approaches for diabetic cardiomyopathy. Cardiovasc Diabetol. 2017;16(1):28. https://doi.org/10.1186/s12933-017-0506-xMarcinkiewicz A., Ostrowski S., Drzewoski J. Can the onset of heart failure be delayed by treating diabetic cardiomyopathy? Diabetol Metab Syndr. 2017;9:21. https://doi.org/10.1186/s13098-017-0219-zMarcinkiewicz A., Ostrowski S., Drzewoski J. Can the onset of heart failure be delayed by treating diabetic cardiomyopathy? Diabetol Metab Syndr. 2017;9:21. https://doi.org/10.1186/s13098-017-0219-zLee W.S., Kim J. Diabetic cardiomyopathy: where we are and where we are going. Korean J Intern Med. 2017;32(3):404- 421. https://doi.org/10.3904/kjim.2016.208.Lee W.S., Kim J. Diabetic cardiomyopathy: where we are and where we are going. Korean J Intern Med. 2017;32(3):404- 421. https://doi.org/10.3904/kjim.2016.208.Dillmann W.H. Diabetic Cardiomyopathy. Circ Res. 2019;124(8):1160-1162. https://doi.org/10.1161/CIRCRESAHA.118.314665Dillmann W.H. Diabetic Cardiomyopathy. Circ Res. 2019;124(8):1160-1162. https://doi.org/10.1161/CIRCRESAHA.118.314665Jia G., Hill M.A., Sowers J.R. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. Circ Res. 2018;122(4):624-638. https://doi.org/10.1161/CIRCRESAHA.117.311586Jia G., Hill M.A., Sowers J.R. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. Circ Res. 2018;122(4):624-638. https://doi.org/10.1161/CIRCRESAHA.117.311586Jia G., DeMarco V.G., Sowers J.R. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 2016;12(3):144-153. https://doi.org/10.1038/nrendo.2015.216Jia G., DeMarco V.G., Sowers J.R. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 2016;12(3):144-153. https://doi.org/10.1038/nrendo.2015.216Mellor K.M., Bell J.R., Ritchie R.H., Delbridge L.M. Myocardial insulin resistance, metabolic stress and autophagy in diabetes. Clin Exp Pharmacol Physiol. 2013;40(1):56-61. https://doi.org/10.1111/j.1440-1681.2012.05738.xMellor K.M., Bell J.R., Ritchie R.H., Delbridge L.M. Myocardial insulin resistance, metabolic stress and autophagy in diabetes. Clin Exp Pharmacol Physiol. 2013;40(1):56-61. https://doi.org/10.1111/j.1440-1681.2012.05738.xGuo R., Nair S. Role of microRNA in diabetic cardiomyopathy: From mechanism to intervention. Biochim Biophys Acta Mol Basis Dis. 2017;1863(8):2070-2077. https://doi.org/10.1016/j.bbadis.2017.03.013Guo R., Nair S. Role of microRNA in diabetic cardiomyopathy: From mechanism to intervention. Biochim Biophys Acta Mol Basis Dis. 2017;1863(8):2070-2077. https://doi.org/10.1016/j.bbadis.2017.03.013Borghetti G., von Lewinski D., Eaton D..M, Sourij H., Houser S.R., Wallner M. Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control. Front Physiol. 2018;9:1514. https://doi.org/10.3389/fphys.2018.01514Borghetti G., von Lewinski D., Eaton D..M, Sourij H., Houser S.R., Wallner M. Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control. Front Physiol. 2018;9:1514. https://doi.org/10.3389/fphys.2018.01514Konduracka E., Cieslik G., Galicka-Latala D., Rostoff P., Pietrucha A., Latacz P., et al. Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes: a 7-year prospective cohort study. Acta Diabetol. 2013;50(4):597-606. https://doi.org/10.1007/s00592-013-0455-0Konduracka E., Cieslik G., Galicka-Latala D., Rostoff P., Pietrucha A., Latacz P., et al. Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes: a 7-year prospective cohort study. Acta Diabetol. 2013;50(4):597-606. https://doi.org/10.1007/s00592-013-0455-0Dandamudi S., Slusser J., Mahoney D.W., Redfield M.M., Rodeheffer R.J., Chen H.H. The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota. J Card Fail. 2014;20(5):304-9. https://doi.org/10.1016/j.cardfail.2014.02.007Dandamudi S., Slusser J., Mahoney D.W., Redfield M.M., Rodeheffer R.J., Chen H.H. The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota. J Card Fail. 2014;20(5):304-9. https://doi.org/10.1016/j.cardfail.2014.02.007Караваев П. Г., Веклич А. С., Козиолова Н. А. Диабетическая кардиомиопатия: особенности сердечно-сосудистого ремоделирования. Российский кардиологический журнал. 2019;24(11):42–47. https://doi.org/10.15829/1560-4071-2019-11-42-47Караваев П. Г., Веклич А. С., Козиолова Н. А. Диабетическая кардиомиопатия: особенности сердечно-сосудистого ремоделирования. Российский кардиологический журнал. 2019;24(11):42–47. https://doi.org/10.15829/1560-4071-2019-11-42-47Kenny H.C., Abel E.D. Heart Failure in Type 2 Diabetes Mellitus. Circ Res. 2019;124(1):121-141. https://doi.org/10.1161/CIRCRESAHA.118.311371Kenny H.C., Abel E.D. Heart Failure in Type 2 Diabetes Mellitus. Circ Res. 2019;124(1):121-141. https://doi.org/10.1161/CIRCRESAHA.118.311371Echouffo-Tcheugui J.B., Xu H., DeVore A.D., Schulte P.J., Butler J., Yancy C.W., et al. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The GuidelinesHeart Failure registry. Am Heart J. 2016;182:9-20. https://doi.org/10.1016/j.ahj.2016.07.025Echouffo-Tcheugui J.B., Xu H., DeVore A.D., Schulte P.J., Butler J., Yancy C.W., et al. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The GuidelinesHeart Failure registry. Am Heart J. 2016;182:9-20. https://doi.org/10.1016/j.ahj.2016.07.025Loncarevic B., Trifunovic D., Soldatovic I., Vujisic-Tesic B. Silent diabetic cardiomyopathy in everyday practice: a clinical and echocardiographic study. BMC Cardiovasc Disord. 2016;16(1):242. https://doi.org/10.1186/s12872-016-0395-zLoncarevic B., Trifunovic D., Soldatovic I., Vujisic-Tesic B. Silent diabetic cardiomyopathy in everyday practice: a clinical and echocardiographic study. BMC Cardiovasc Disord. 2016;16(1):242. https://doi.org/10.1186/s12872-016-0395-zSeferović P.M., Paulus W.J. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015;36(27):1718-1727c. https://doi.org/10.1093/eurheartj/ehv134/Seferović P.M., Paulus W.J. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015;36(27):1718-1727c. https://doi.org/10.1093/eurheartj/ehv134/Fang Z.Y., Prins J.B., Marwick T.H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev. 2004;25(4):543-567. https://doi.org/10.1210/er.2003-0012Fang Z.Y., Prins J.B., Marwick T.H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev. 2004;25(4):543-567. https://doi.org/10.1210/er.2003-0012Negishi K. Echocardiographic feature of diabetic cardiomyopathy: where are we now? Cardiovasc Diagn Ther. 2018;8(1):47-56. https://doi.org/10.21037/cdt.2018.01.03Negishi K. Echocardiographic feature of diabetic cardiomyopathy: where are we now? Cardiovasc Diagn Ther. 2018;8(1):47-56. https://doi.org/10.21037/cdt.2018.01.03Alonso N., Moliner P., Mauricio D. Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy. Adv Exp Med Biol. 2018;1067:197-217. https://doi.org/10.1007/5584_2017_105Alonso N., Moliner P., Mauricio D. Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy. Adv Exp Med Biol. 2018;1067:197-217. https://doi.org/10.1007/5584_2017_105Gil K.E., Pawlak A., Gil R.J., Frontczak-Baniewicz M., Bil J. The role of invasive diagnostics and its impact on the treatment of dilated cardiomyopathy: A systematic review. Adv Med Sci. 2016;61(2):331-343. https://doi.org/10.1016/j.advms.2016.07.001Gil K.E., Pawlak A., Gil R.J., Frontczak-Baniewicz M., Bil J. The role of invasive diagnostics and its impact on the treatment of dilated cardiomyopathy: A systematic review. Adv Med Sci. 2016;61(2):331-343. https://doi.org/10.1016/j.advms.2016.07.001Guo R., Nair S. Role of microRNA in diabetic cardiomyopathy: From mechanism to intervention. Biochim Biophys Acta Mol Basis Dis. 2017;1863(8):2070-2077. https://doi.org/10.1016/j.bbadis.2017.03.013Guo R., Nair S. Role of microRNA in diabetic cardiomyopathy: From mechanism to intervention. Biochim Biophys Acta Mol Basis Dis. 2017;1863(8):2070-2077. https://doi.org/10.1016/j.bbadis.2017.03.013Ghosh N., Katare R. Molecular mechanism of diabetic cardiomyopathy and modulation of microRNA function by synthetic oligonucleotides. Cardiovasc Diabetol. 2018;17(1):43. https://doi.org/10.1186/s12933-018-0684-1Ghosh N., Katare R. Molecular mechanism of diabetic cardiomyopathy and modulation of microRNA function by synthetic oligonucleotides. Cardiovasc Diabetol. 2018;17(1):43. https://doi.org/10.1186/s12933-018-0684-1Hafstad A.D., Boardman N., Aasum E. How exercise may amend metabolic disturbances in diabetic cardiomyopathy. Antioxid Redox Signal. 2015;22(17):1587- 1605. https://doi.org/10.1089/ars.2015.6304Hafstad A.D., Boardman N., Aasum E. How exercise may amend metabolic disturbances in diabetic cardiomyopathy. Antioxid Redox Signal. 2015;22(17):1587- 1605. https://doi.org/10.1089/ars.2015.6304Waldman M., Cohen K., Yadin D., Nudelman V., Gorfil D., Laniado-Schwartzman M., et al. Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving 'SIRT1 and PGC-1α'. Cardiovasc Diabetol. 2018;17(1):111. https://doi.org/10.1186/s12933-018-0754-4Waldman M., Cohen K., Yadin D., Nudelman V., Gorfil D., Laniado-Schwartzman M., et al. Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving 'SIRT1 and PGC-1α'. Cardiovasc Diabetol. 2018;17(1):111. https://doi.org/10.1186/s12933-018-0754-4Chen Q., Thompson J., Hu Y., Das A., Lesnefsky EJ. Metformin attenuates ER stress-induced mitochondrial dysfunction. Transl Res. 2017;190:40-50. https://doi.org/10.1016/j.trsl.2017.09.003Chen Q., Thompson J., Hu Y., Das A., Lesnefsky EJ. Metformin attenuates ER stress-induced mitochondrial dysfunction. Transl Res. 2017;190:40-50. https://doi.org/10.1016/j.trsl.2017.09.003Borghetti G., von Lewinski D., Eaton D.M., Sourij H., Houser S.R., Wallner M. Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control. Front Physiol. 2018;9:1514. https://doi.org/10.3389/fphys.2018.01514Borghetti G., von Lewinski D., Eaton D.M., Sourij H., Houser S.R., Wallner M. Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control. Front Physiol. 2018;9:1514. https://doi.org/10.3389/fphys.2018.01514Wu L., Wang K., Wang W., Wen Z., Wang P., Liu L., Wang D.W. Glucagon-like peptide-1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPARα pathway. Aging Cell. 2018;17(4):e12763. https://doi.org/10.1111/acel.12763Wu L., Wang K., Wang W., Wen Z., Wang P., Liu L., Wang D.W. Glucagon-like peptide-1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPARα pathway. Aging Cell. 2018;17(4):e12763. https://doi.org/10.1111/acel.12763Levelt E., Gulsin G., Neubauer S., McCann G.P. MECHANISMS IN ENDOCRINOLOGY: Diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review. Eur J Endocrinol. 2018;178(4):R127-R139. https://doi.org/10.1530/EJE-17-0724Levelt E., Gulsin G., Neubauer S., McCann G.P. MECHANISMS IN ENDOCRINOLOGY: Diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review. Eur J Endocrinol. 2018;178(4):R127-R139. https://doi.org/10.1530/EJE-17-0724Pan G., Deshpande M., Pang H., Palaniyandi S.S. Precision medicine approach: Empagliflozin for diabetic cardiomyopathy in mice with aldehyde dehydrogenase (ALDH) 2 * 2 mutation, a specific genetic mutation in millions of East Asians. Eur J Pharmacol. 2018;839:76-81. https://doi.org/10.1016/j.ejphar.2018.09.021Pan G., Deshpande M., Pang H., Palaniyandi S.S. Precision medicine approach: Empagliflozin for diabetic cardiomyopathy in mice with aldehyde dehydrogenase (ALDH) 2 * 2 mutation, a specific genetic mutation in millions of East Asians. Eur J Pharmacol. 2018;839:76-81. https://doi.org/10.1016/j.ejphar.2018.09.021Liu W., Gong W., He M., Liu Y., Yang Y., Wang M., et al. Spironolactone Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Rats. J Diabetes Res. 2018;2018:9232065. https://doi.org/10.1155/2018/9232065Liu W., Gong W., He M., Liu Y., Yang Y., Wang M., et al. Spironolactone Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Rats. J Diabetes Res. 2018;2018:9232065. https://doi.org/10.1155/2018/9232065Sivasankar D., George M., Sriram D.K. Novel approaches in the treatment of diabetic cardiomyopathy. Biomed Pharmacother. 2018;106:1039-1045. https://doi.org/10.1016/j.biopha.2018.07.051Sivasankar D., George M., Sriram D.K. Novel approaches in the treatment of diabetic cardiomyopathy. Biomed Pharmacother. 2018;106:1039-1045. https://doi.org/10.1016/j.biopha.2018.07.051Yilmaz S., Canpolat U., Aydogdu S., Abboud H.E. Diabetic Cardiomyopathy; Summary of 41 Years. Korean Circ J. 2015;45(4):266-272. https://doi.org/10.4070/kcj.2015.45.4.266Yilmaz S., Canpolat U., Aydogdu S., Abboud H.E. Diabetic Cardiomyopathy; Summary of 41 Years. Korean Circ J. 2015;45(4):266-272. https://doi.org/10.4070/kcj.2015.45.4.266Di Luigi L., Corinaldesi C., Colletti M., Scolletta S., Antinozzi C., Vannelli G.B., et al. Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy. Inflammation. 2016;39(3):1238- 52. https://doi.org/10.1007/s10753-016-0359-6Di Luigi L., Corinaldesi C., Colletti M., Scolletta S., Antinozzi C., Vannelli G.B., et al. Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy. Inflammation. 2016;39(3):1238- 52. https://doi.org/10.1007/s10753-016-0359-6Carillion A., Feldman S., Na N., Biais M., Carpentier W., Birenbaum A., et al. Atorvastatin reduces β-Adrenergic dysfunction in rats with diabetic cardiomyopathy. PLoS One. 2017;12(7):e0180103. https://doi.org/10.1371/journal.pone.0180103Carillion A., Feldman S., Na N., Biais M., Carpentier W., Birenbaum A., et al. Atorvastatin reduces β-Adrenergic dysfunction in rats with diabetic cardiomyopathy. PLoS One. 2017;12(7):e0180103. https://doi.org/10.1371/journal.pone.0180103Yang H., Feng A., Lin S., Yu L., Lin X., Yan X., et al. Fibroblast growth factor-21 prevents diabetic cardiomyopathy via AMPK-mediated antioxidation and lipid-lowering effects in the heart. Cell Death Dis. 2018;9(2):227. https://doi.org/10.1038/s41419-018-0307-5Yang H., Feng A., Lin S., Yu L., Lin X., Yan X., et al. Fibroblast growth factor-21 prevents diabetic cardiomyopathy via AMPK-mediated antioxidation and lipid-lowering effects in the heart. Cell Death Dis. 2018;9(2):227. https://doi.org/10.1038/s41419-018-0307-5Zhang L., Ding W.Y., Wang Z.H., Tang M.X., Wang F., Li Y., et al. Early administration of trimetazidine attenuates diabetic cardiomyopathy in rats by alleviating fibrosis, reducing apoptosis and enhancing autophagy. J Transl Med. 2016;14(1):109. https://doi.org/10.1186/s12967-016-0849-1Zhang L., Ding W.Y., Wang Z.H., Tang M.X., Wang F., Li Y., et al. Early administration of trimetazidine attenuates diabetic cardiomyopathy in rats by alleviating fibrosis, reducing apoptosis and enhancing autophagy. J Transl Med. 2016;14(1):109. https://doi.org/10.1186/s12967-016-0849-1Gollmer J., Zirlik A., Bugger H. Mitochondrial Mechanisms in Diabetic Cardiomyopathy. Diabetes Metab J. 2020;44(1):33- 53. https://doi.org/10.4093/dmj.2019.0185Gollmer J., Zirlik A., Bugger H. Mitochondrial Mechanisms in Diabetic Cardiomyopathy. Diabetes Metab J. 2020;44(1):33- 53. https://doi.org/10.4093/dmj.2019.0185Tian J., Zhao Y., Liu Y., Liu Y., Chen K., Lyu S. Roles and Mechanisms of Herbal Medicine for Diabetic Cardiomyopathy: Current Status and Perspective. Oxid Med Cell Longev. 2017;2017:8214541. https://doi.org/10.1155/2017/8214541Tian J., Zhao Y., Liu Y., Liu Y., Chen K., Lyu S. Roles and Mechanisms of Herbal Medicine for Diabetic Cardiomyopathy: Current Status and Perspective. Oxid Med Cell Longev. 2017;2017:8214541. https://doi.org/10.1155/2017/8214541Fang W.J., Wang C.J., He Y., Zhou Y.L., Peng X.D., Liu S.K. Resveratrol alleviates diabetic cardiomyopathy in rats by improving mitochondrial function through PGC-1α deacetylation. Acta Pharmacol Sin. 2018;39(1):59-73. https://doi.org/10.1038/aps.2017.50Fang W.J., Wang C.J., He Y., Zhou Y.L., Peng X.D., Liu S.K. Resveratrol alleviates diabetic cardiomyopathy in rats by improving mitochondrial function through PGC-1α deacetylation. Acta Pharmacol Sin. 2018;39(1):59-73. https://doi.org/10.1038/aps.2017.50Wen H.L., Liang Z.S., Zhang R., Yang K. Anti-inflammatory effects of triptolide improve left ventricular function in a rat model of diabetic cardiomyopathy. Cardiovasc Diabetol. 2013;12:50. https://doi.org/10.1186/1475-2840-12-50Wen H.L., Liang Z.S., Zhang R., Yang K. Anti-inflammatory effects of triptolide improve left ventricular function in a rat model of diabetic cardiomyopathy. Cardiovasc Diabetol. 2013;12:50. https://doi.org/10.1186/1475-2840-12-50Huynh K., Bernardo B.C., McMullen J.R., Ritchie R.H. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther. 2014;142(3):375-415. https://doi.org/10.1016/j.pharmthera.2014.01.003.Huynh K., Bernardo B.C., McMullen J.R., Ritchie R.H. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther. 2014;142(3):375-415. https://doi.org/10.1016/j.pharmthera.2014.01.003.Park I.H., Song Y.S., Joo H.W., Shen G.Y., Seong J.H., Shin N.K., et al. Role of MicroRNA-34a in Anti-Apoptotic Effects of Granulocyte-Colony Stimulating Factor in Diabetic Cardiomyopathy. Diabetes Metab J. 2020;44(1):173-185. https://doi.org/10.4093/dmj.2018.0211Park I.H., Song Y.S., Joo H.W., Shen G.Y., Seong J.H., Shin N.K., et al. Role of MicroRNA-34a in Anti-Apoptotic Effects of Granulocyte-Colony Stimulating Factor in Diabetic Cardiomyopathy. Diabetes Metab J. 2020;44(1):173-185. https://doi.org/10.4093/dmj.2018.0211

The authors declare that there are no conflicts of interest present.